tiprankstipranks
Niagen Bioscience (DE:OCD1)
FRANKFURT:OCD1
Germany Market
OCD1
Niagen Bioscience
RESEARCH TOOLSreports

Niagen Bioscience (OCD1) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

OCD1 Analyst Ratings

Strong Buy
5Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Niagen
Bioscience
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

OCD1 Stock 12 Month Forecast

Average Price Target

€9.32
▲(263.98% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Niagen Bioscience in the last 3 months. The average price target is €9.32 with a high forecast of €10.55 and a low forecast of €7.91. The average price target represents a 263.98% change from the last price of €2.56.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","12":"€12","3.75":"€3.75","6.5":"€6.5","9.25":"€9.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10.54848612,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€10.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.317829406,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€9.32</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.91136459,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€7.91</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3.75,6.5,9.25,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.52,3.1375758553846156,3.7551517107692307,4.372727566153846,4.990303421538462,5.607879276923077,6.225455132307692,6.843030987692307,7.460606843076922,8.078182698461537,8.695758553846153,9.31333440923077,9.930910264615385,{"y":10.54848612,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.52,3.0429099543076923,3.5658199086153846,4.088729862923077,4.611639817230769,5.134549771538461,5.657459725846154,6.180369680153846,6.703279634461538,7.2261895887692305,7.749099543076923,8.272009497384614,8.794919451692307,{"y":9.317829406,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.52,2.9347203530769232,3.349440706153846,3.7641610592307693,4.1788814123076925,4.593601765384616,5.008322118461539,5.423042471538462,5.837762824615385,6.252483177692309,6.667203530769232,7.081923883846155,7.496644236923077,{"y":7.91136459,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.15,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.15,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.85,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.55,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.76,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.98,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.58,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.8,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.2,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 51, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.52,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 66,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 51, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€10.55Average Price Target€9.32Lowest Price Target€7.91
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Roth MKM Analyst forecast on DE:OCD1
Sean McGowan
Roth MKM
Roth MKM
€10.55
Buy
312.05%
Upside
Reiterated
07/27/26
Niagen Bioscience (NAGE) Gets a Buy from Roth MKM
Ladenburg Thalmann & Co. Analyst forecast on DE:OCD1
Jeffrey Cohen
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
€10.55→€9.67
Buy
277.71%
Upside
Reiterated
07/21/26
Niagen Bioscience price target lowered to $11 from $12 at LadenburgNiagen Bioscience price target lowered to $11 from $12 at Ladenburg
H.C. Wainwright Analyst forecast on DE:OCD1
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
€9.67
Buy
277.71%
Upside
Reiterated
07/09/26
Niagen Bioscience: Buy Rating Reiterated as Pipeline Advances; 12-Month Price Target Unchanged at $11
Freedom Capital Markets Analyst forecast on DE:OCD1
Ilya Zubkov
Freedom Capital Markets
Freedom Capital Markets
€7.91
Buy
209.04%
Upside
Initiated
07/06/26
Niagen Bioscience initiated with a Buy at Freedom BrokerNiagen Bioscience initiated with a Buy at Freedom Broker
Canaccord Genuity Analyst forecast on DE:OCD1
Susan Anderson
Canaccord Genuity
Canaccord Genuity
€8.79
Buy
243.38%
Upside
Reiterated
05/28/26
Analysts Are Bullish on Top Healthcare Stocks: Niagen Bioscience (NAGE), Guardant Health (GH)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Roth MKM Analyst forecast on DE:OCD1
Sean McGowan
Roth MKM
Roth MKM
€10.55
Buy
312.05%
Upside
Reiterated
07/27/26
Niagen Bioscience (NAGE) Gets a Buy from Roth MKM
Ladenburg Thalmann & Co. Analyst forecast on DE:OCD1
Jeffrey Cohen
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
€10.55→€9.67
Buy
277.71%
Upside
Reiterated
07/21/26
Niagen Bioscience price target lowered to $11 from $12 at LadenburgNiagen Bioscience price target lowered to $11 from $12 at Ladenburg
H.C. Wainwright Analyst forecast on DE:OCD1
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
€9.67
Buy
277.71%
Upside
Reiterated
07/09/26
Niagen Bioscience: Buy Rating Reiterated as Pipeline Advances; 12-Month Price Target Unchanged at $11
Freedom Capital Markets Analyst forecast on DE:OCD1
Ilya Zubkov
Freedom Capital Markets
Freedom Capital Markets
€7.91
Buy
209.04%
Upside
Initiated
07/06/26
Niagen Bioscience initiated with a Buy at Freedom BrokerNiagen Bioscience initiated with a Buy at Freedom Broker
Canaccord Genuity Analyst forecast on DE:OCD1
Susan Anderson
Canaccord Genuity
Canaccord Genuity
€8.79
Buy
243.38%
Upside
Reiterated
05/28/26
Analysts Are Bullish on Top Healthcare Stocks: Niagen Bioscience (NAGE), Guardant Health (GH)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
ZURAZura Bio
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Niagen Bioscience

3 Months
Jeffrey CohenLadenburg Thalmann & Co.
Success Rate
6/12 ratings generated profit
50%
Average Return
+0.42%
reiterated a buy rating 12 days ago
Copying Jeffrey Cohen's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +0.42% per trade.
1 Year
Jeffrey CohenLadenburg Thalmann & Co.
Success Rate
4/12 ratings generated profit
33%
Average Return
+32.33%
reiterated a buy rating 12 days ago
Copying Jeffrey Cohen's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +32.33% per trade.
2 Years
Jeffrey CohenLadenburg Thalmann & Co.
Success Rate
4/12 ratings generated profit
33%
Average Return
+45.29%
reiterated a buy rating 12 days ago
Copying Jeffrey Cohen's trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of +45.29% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OCD1 Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
7
6
9
6
10
Buy
14
6
27
56
56
Hold
15
12
32
51
51
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
36
24
68
113
117
In the current month, OCD1 has received 66 Buy Ratings, 51 Hold Ratings, and 0 Sell Ratings. OCD1 average Analyst price target in the past 3 months is 9.32.
Each month's total comprises the sum of three months' worth of ratings.

OCD1 Financial Forecast

OCD1 Earnings Forecast

Next quarter’s earnings estimate for OCD1 is <€0.01 with a range of >-€0.01 to €0.03. The previous quarter’s EPS was €0.06. OCD1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year OCD1 has Performed in-line its overall industry.
Next quarter’s earnings estimate for OCD1 is <€0.01 with a range of >-€0.01 to €0.03. The previous quarter’s EPS was €0.06. OCD1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year OCD1 has Performed in-line its overall industry.

OCD1 Sales Forecast

Next quarter’s sales forecast for OCD1 is €26.47M with a range of €25.22M to €27.65M. The previous quarter’s sales results were €27.28M. OCD1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.23% of the time in the same period. In the last calendar year OCD1 has Performed in-line its overall industry.
Next quarter’s sales forecast for OCD1 is €26.47M with a range of €25.22M to €27.65M. The previous quarter’s sales results were €27.28M. OCD1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.23% of the time in the same period. In the last calendar year OCD1 has Performed in-line its overall industry.

OCD1 Stock Forecast FAQ

What is DE:OCD1’s average 12-month price target, according to analysts?
Based on analyst ratings, Niagen Bioscience’s 12-month average price target is 9.32.
    What is DE:OCD1’s upside potential, based on the analysts’ average price target?
    Niagen Bioscience has 263.98% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Niagen Bioscience a Buy, Sell or Hold?
          Niagen Bioscience has a consensus rating of Strong Buy, which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Niagen Bioscience’s share price target?
            The average share price target for Niagen Bioscience is 9.32. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €10.55 ,and the lowest forecast is €7.91. The average share price target represents 263.98% Increase from the current price of €2.56.
              What do analysts say about Niagen Bioscience?
              Niagen Bioscience’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of Niagen Bioscience?
                To buy shares of DE:OCD1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.